Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fugenbio Co. Ltd. currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is handled by 1 distinct examiner, NESTOR, DONNA MICHELLE, who is identified as the busiest examiner for the portfolio with 1 pending case. The prosecution footprint is highly concentrated, as the portfolio is active in only 1 distinct art unit.
For a practitioner, this level of concentration suggests that the outcome of the entire pending portfolio depends on the specific tendencies and requirements of a single individual. Because there is only 1 distinct examiner involved, there is no opportunity to compare examiner behaviors across different applications within the company. The presence of 1 pending office action indicates a focused and limited engagement with the patent office at this time.
The alignment of 1 distinct art unit and 1 distinct examiner simplifies the administrative burden of tracking multiple deadlines or varying examiner preferences. However, it also means that the company has not yet diversified its intellectual property efforts across different technical sub-groups or examination teams. Strategy should focus on the specific precedents and examination styles prevalent in the single art unit where the 1 pending action resides.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NESTOR, DONNA MICHELLE | 1 | 56.6% | +44.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861273 | METHOD FOR PREPARATION OF COMPOUND POSSESSING 5-PENTYLFURFURAL (5-PF) STRUCTURE AND USE THEREOF | NESTOR, DONNA MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18861273 | METHOD FOR PREPARATION OF COMPOUND POSSESSING 5-PENTYLFURFURAL (5-PF) STRUCTURE AND USE THEREOF | NESTOR, DONNA MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18861273 | METHOD FOR PREPARATION OF COMPOUND POSSESSING 5-PENTYLFURFURAL (5-PF) STRUCTURE AND USE THEREOF | NESTOR, DONNA MICHELLE | 1627 | §102§112 | Non-Final OA | — | Pending | Oct 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFugenbio Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Donna Michelle Nestor has the most, with 1 of Fugenbio Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
